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Pulmonary Vein-to-Pulmonary Artery Ratio is an Echocardiographic
Index of Congestive Heart Failure in Dogs with Degenerative Mitral
Valve Disease
A.-C. Merveille, G. Bolen, E. Kraﬀt, E. Roels, S. Gomart, A.-L. Etienne, C. Clercx, and K. Mc Entee
Background: Early recognition of left-sided congestive heart failure (CHF) in dogs with degenerative mitral valve disease
(DMVD) is important because it inﬂuences medical therapy, timing of follow-up, and outcome.
Hypothesis: Pulmonary vein diameter-to-pulmonary artery diameter ratio (PV/PA) measured by echocardiography can
predict CHF.
Animals: Ninety-eight client-owned dogs, 37 controls, and 61 dogs with DMVD.
Methods: Prospective clinical cohort study. History, physical examination and Doppler-echocardiography were per-
formed. Dogs were classiﬁed as International Small Animal Cardiac Health Council class I, II or III. Congestive heart failure
was identiﬁed in a subset of 56 dogs based on radiographic ﬁndings. The PV/PA was measured in bidimensional (2D) and
M-mode by 2 investigators blinded to the radiologists’ conclusions.
Results: Interobserver coeﬃcients of variation for PV/PA acquisition and measurement were <10%. The PV/PA in con-
trol dogs was approximately 1 and increased with class of heart failure. The presence of CHF could be best predicted by
measuring PV/PA in 2D echocardiography (cut-oﬀ, 1.7; area under the curve, 0.98; CI, 0.97–0.98; P < .001) with a sensitivity
of 96% and a speciﬁcity of 91%.
Conclusion and clinical importance: The PV/PA is a simple and reproducible echocardiographic variable that increases
with class of heart failure and may help discriminate dogs in CHF from asymptomatic dogs with DMVD. Additional studies
are required to determine whether PV/PA might provide additional information in the integrated interpretation of Doppler-
echocardiographic indices of left ventricular ﬁlling pressures and could be used for rapid assessment of CHF in dogs in a crit-
ical care setting.
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Degenerative mitral valve disease (DMVD) is themost common form of acquired heart disease in
dogs.1 The course of the disease is highly variable with
most dogs spending several years in an asymptomatic
state. Approximately one-third of aﬀected dogs develop
congestive heart failure (CHF) and die.2 Early recogni-
tion of CHF is important because it enables initiation
of conventional therapy in accordance with expert rec-
ommendations,3 the avoidance of life-threatening situa-
tions, and limitation of hospitalization costs. Clinical
variables, such as resting respiratory rate, can predict
cardiac decompensation,4 but no clinical sign is CHF-
speciﬁc. Thoracic radiography is considered the clinical
“gold standard”, but important interreader variability
exists. Diagnosis of CHF should not rely solely on
radiographic determination of pulmonary edema.5,6 The
N-terminal probrain natriuretic peptide (NT-proBNP)
biomarker may contribute to the diagnosis of CHF.
The NT-proBNP concentration correlates with DMVD
severity7,8 and has been shown to help distinguish dogs
with respiratory signs caused by CHF from those with
respiratory disease.9,10 However, a wide overlap exists
between asymptomatic dogs and dogs in CHF,9,11,12
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ACEI angiotensin converting enzyme inhibitor
AUC area under the curve
Ao aorta
BW body weight
CHF congestive heart failure
CI conﬁdence interval
CV coeﬃcient of variation
DMVD degenerative mitral valve disease
E/A maximal velocity of early left ventricular diastolic
ﬁlling/maximal velocity of active ﬁlling
EDVI indexed end-diastolic volume
IQR interquartile range
ISACHC international Small Animal Cardiac Health Council
LA left atrium
nLVIDd normalized left ventricular internal diameter in diastole
MM m-mode
NT-proBNP n-terminal probrain natriuretic peptide
PA pulmonary artery
PV pulmonary vein
PV/PA pulmonary vein to pulmonary artery ratio
SD standard deviation
TR tricuspid regurgitation
VHS vertebral heart score
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and a small proportion of healthy dogs have high con-
centrations of NT-proBNP.13 Furthermore, day-to-
day14 and interbreed15 variations exist. Doppler
echocardiography may conﬁrm DMVD diagnosis and
detect dogs in CHF. In dogs with DMVD, peak E to
isovolumic relaxation time ratio and diastolic functional
class are sensitive markers of CHF.16 However, these
measurements require operator expertise. All of these
single diagnostic tools have their own limitations, and
obtaining a deﬁnitive diagnosis often relies on a combi-
nation of test results.10,16 Therefore, the development of
an additional, easy-to-measure, echocardiographic index
might improve early recognition of CHF in dogs.
The pulmonary vein-to-pulmonary artery ratio (PV/
PA) is a novel echocardiographic variable that might
distinguish dogs in CHF from those in a compensated
state.17 In dogs with progressive DMVD leading to
CHF, we would anticipate that increased pulmonary
venous pressure associated with venous enlargement
would cause an increase in the PV/PA ratio. Therefore,
we ﬁrst established normal values for PV, PA, and the
PV/PA ratio in control dogs of various sizes and deter-
mined the correlation between the PV/PA ratio assessed
by bidimensional (2D) and M-mode (MM) echocardiog-
raphy. Thereafter, we assessed the eﬀect of the class of
heart failure on this ratio and determined if PV/PA
could be used to identify CHF in dogs with DMVD.
Material and Methods
Dogs
Control and diseased dogs were prospectively recruited (from
October 2011 until May 2015) at the Clinical Veterinary Hospital
of the University of Liege. Inclusion criteria for aﬀected dogs
included the presence of a typical heart murmur and an echocardio-
graphic diagnosis of DMVD, characterized by degenerative changes
of the mitral valve leaﬂets, mitral valve prolapse and the presence
of systolic regurgitant ﬂow.18 Control dogs were recruited during
routine consultations or belonged to staﬀ members. A thorough his-
tory was taken for all dogs before physical examination and Dop-
pler echocardiography. Dogs with evidence of a concomitant
disease were excluded. Dogs with DMVD were classiﬁed into class
I, II, or III according to the International Small Animal Cardiac
Health Council (ISACHC) classiﬁcation system.19 Class I was
deﬁned as subclinical heart disease without (IA) or with (IB) evi-
dence of left cardiomegaly. Class II was deﬁned as mild to moderate
CHF in the presence of radiographic abnormalities consistent with
pulmonary edema. Class III was deﬁned as overt, severe CHF.
Doppler Echocardiography
Transthoracic 2D, MM echocardiography and conventional
Doppler echocardiography were performed by 2 trained observers
(1 board-certiﬁed cardiologist [KME] and 1 cardiology resident
[ACM] using an ultrasound unita equipped with 2.2–3.5 and 5.5–
7.5 MHz phased-array transducers. Dogs were placed in right and
left lateral recumbency and a simultaneous 1-lead electrocardio-
gram was recorded. Standard right parasternal (long and short
axis) and left apical parasternal views were used for data acquisi-
tion. Left atrial size was assessed in the right parasternal long axis
view using the septal-to-caudal dimension of the left atrium
(LAmin) and in right parasternal short axis at the level of the
aorta (LA). Both measurements were taken at the end of systole
and were normalized using aortic diameter (Ao) (LAmin/Ao and
LA/Ao, respectively). End-diastolic left ventricular volume was
calculated from the right parasternal long axis view using modiﬁed
Simpson’s rule20 and indexed to body surface area (EDVI). Left
ventricular end-diastolic diameter was measured in MM from a
left ventricular short axis view at the level of chordae tendinae and
indexed to body weight using the Cornell method (nLVIDd).21
Mitral inﬂow was recorded using pulsed-wave Doppler from the
left apical parasternal 4-chamber view (E, A and E/A). The tricus-
pid valve was systematically evaluated for evidence of regurgita-
tion. If a tricuspid regurgitant (TR) jet was visible, its velocity was
recorded and transformed into a pressure gradient according to
the modiﬁed Bernoulli equation. Pulmonary hypertension was
deﬁned as a TR pressure gradient >36 mmHg (TR > 3 m/s). All
measurements were performed oﬀ-line by a single trained investi-
gator (KME) blinded to clinical signs and thoracic radiographic
scores.
Acquisition and Reproducibility of PV/PA Ratio
For PV/PA measurement, a right parasternal long axis 4-cham-
ber view was optimized to simultaneously visualize a longitudinal
section of the medial PV and the right PA in cross-section and
recorded. Measurements of PV and PA diameters were taken in
MM as previously described17 and in 2D. Dimensions were
obtained by tracing a line perpendicular to the medial PV and
passing through the center of the adjacent right PA. For both
measurements, we used the inner edge-to-inner edge method at the
end of the T wave (Fig 1). Three measurements were averaged.
Interobserver variability of PV/PA image acquisition and of PV/
PA measurement were assessed separately in 10 and 20 dogs,
respectively.
Thoracic Radiography
Thoracic radiographs (right lateral, left lateral, and dorso-ventral
projections) were taken in a subset of dogs. A board-certiﬁed
A
B
Fig 1. Illustration of pulmonary vein diameter (*) and right pul-
monary artery diameter (**) measurements in bidimensional (A)
and M-mode (B) using the inner edge to inner edge method.
PV/PA in Degenerative Mitral Valve Disease 1503
radiologist (GB) and a radiologist with extensive expertise (ALE)
reviewed the images independently. All studies were randomly
ordered and radiologists were blinded to the animal’s identiﬁcation,
the date of examination, the initial interpretation of images, and the
echocardiographic ﬁndings. A radiographic composite CHF score
was assigned to each patient. This score was based on 3 main crite-
ria: evidence of cardiomegaly, lung pattern, and pulmonary venous
congestion. Speciﬁcally, cardiomegaly criteria were subdivided as
follows: qualitative assessment of the cardiac silhouette, vertebral
heart score,22 and presence of left atrial enlargement. A car-
diomegaly score of 0 was given when the cardiac silhouette was con-
sidered normal; a score of 1 was given when moderate
cardiomegaly was present; and, a score of 2 was given when severe
cardiomegaly was present. Lung pattern was assessed with a score
varying from 0 to 3, with 0 corresponding to a normal lung pattern,
1 to a moderate to severe interstitial pattern, 2 to a localized alveo-
lar pattern, and 3 to a diﬀuse alveolar pattern. Venous congestion
also was assessed with a score between 0 and 2, with 0 correspond-
ing to the absence of venous congestion, 1 for moderate venous
congestion (not evident in all pulmonary veins), and 2 for severe
venous congestion. A ﬁnal cumulative score between 0 and 7 was
allocated to each dog. The ﬁnal radiographic assessment also deter-
mined if CHF was present or absent. Results of the 2 radiologists
were compared and, if there was disagreement with regard to the
presence or absence of CHF, images were reviewed by both radiolo-
gists together to provide a ﬁnal consensus.
Statistical Analysis
Statistical analysis was performed using the xlstatb software.
Statistical signiﬁcance was set at P < .05. Normality was tested
using the Shapiro–Wilk test. Continuous data were expressed as
median values with interquartile range (IQR, 25th to 75th per-
centiles). The interobserver variability of image acquisition and
measurements was calculated using coeﬃcients of variation (CV)
with the formula: CV = standard deviation of measurement/mean
of measurement 9 100 (%). The PV/PA measurements obtained
from 2D and MM were compared using a paired Mann–Whitney
log rank test. Nonlinear regression analyses were used to identify
and quantify relationships between PV or PA and body weight.
Proportions were compared by a chi-squared test. A Mann–Whit-
ney log rank test was used to compare continuous demographic
data between control and aﬀected dogs, and PV/PA between
asymptomatic and CHF dogs. Pearson or Spearman correlations
were used, according to data distribution, to test the strength of
the relationship between PV/PA measured by the 2 methods and
other echocardiographic parameters. A Kruskal–Wallis test with
Bonferroni’s adjustment (corrected P value .005) was used to com-
pare PV/PA among classes of heart failure. Receiver-operating
characteristic (ROC) curve analysis was used to determine the




Ninety-eight dogs were enrolled in the study includ-
ing 37 controls and 61 dogs with DMVD. In the con-
trol group, the most common breeds were crossbreed
(7), Jack Russell Terrier (4), Beagle (3), Dachshund (3),
West Highland white terrier (3), American Staﬀordshire
(2), Labrador (2), and Yorkshire terrier (2). In dogs
with DMVD, the most common breeds were Cavalier
King Charles Spaniel (14), crossbreed (7), Jack Russell
terrier (5), Bichon Frise (5), Beagle (4), Dachshund (3),
Shih-Tzu (3), Chihuahua (3), Lhasa Apso (2), and
Yorkshire terrier (2). Control dogs (6.1 years old;
range, 3.9-9.6) were signiﬁcantly younger and included
more females (21/37) than aﬀected dogs (10 years old;
range, 8.6–12.3; P = .001; female, 22/61; P = .045). No
signiﬁcant diﬀerence was found for body weight. Demo-
graphic data, historical ﬁndings, and physical examina-
tion results for the DMVD dogs are summarized in
Table 1. At presentation, 4 (25%) dogs of class IA and
5 (31%) dogs of class IB were being treated with an
angiotensin converting enzyme inhibitors (ACEI). One
dog of class IB was also receiving pimobendan (6%). In
classes II and III, 13 (65%) and 4 dogs (44%), respec-
tively, had received furosemide before examination. Fif-
teen (75%) dogs in class II and 4 (44%) dogs in class
III were being treated with an ACEI, whereas 10 (50%)
and 2 (22%) dogs were receiving pimobendan. Three
(15%) dogs in class II and 2 (22%) dogs in class III
had received spironolactone.
PV/PA: Variability and Reference Intervals
Interobserver CV for image acquisition of PV, PA
and PV/PA were, respectively, 8, 4 and 8% in 2D and
4, 5 and 7% in MM. Interobserver CV for PV, PA and
Table 1. Demographic data, history ﬁndings, and the results of physical examination in 61 dogs with degenerative
mitral valve disease.
ISACHC IA ISACHC IB ISACHC II ISACHC III
Number 16 16 20 9
Age (years) 10.3 (6.0–11.6) 9.1 (8.5–11.0) 10.3 (9.0–12.4) 11.1 (7.5–12.3)
Body weight (kg) 10.4 (7.3–13.1) 11.4 (8.0–14.4) 8.4 (7.0–11.5) 7.6 (5.9–11.2)
Sex (male : female) 9 : 7 11 : 5 14 : 6 5 : 4
Cough (%) 1 (6) 4 (25) 13 (65) 8 (89)
Exercise intolerance (%) 1 (6 / 13 (65) 7 (78)
Tachypnea/Dyspnea (%) / 1 (6) 6 (30%) 8 (89)
Syncope (%) / / 6 (30) 2 (22)
RR (breaths/min) 28 (24–32) 24 (24–30) 36 (24–48) 52 (42–84)
HR (beats/min) 102 (80–120) 110 (88–120) 132 (120–147) 160 (120–180)
Murmur grade (0/6–6/6) 3 (1–4) 4 (3–4) 5 (4–6) 5 (4–5)
Median (IQR) for continuous data, median (range) for categorical data and number of dogs (%) for frequency data. HR, heart rate;
IQR, interquartile range; ISACHC, International Small Animal Cardiac Health Council; RR, respiratory rate.
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PV/PA measurements were, respectively, 7, 9 and 9% in
2D 6, 9 and 9% in MM.
In healthy dogs, PV and PA measured in 2D and
MM were correlated with body weight; no correlation
was found for PV/PA (Fig 2). No signiﬁcant diﬀerence
was observed between PV/PA obtained in 2D or MM
and both methods were highly correlated (r = 0.90;
P < .001; Fig 3). The PV/PA ratio for control dogs was
1.01 (range, 0.95–1.06) in 2D and 1.01 (range, 0.95–
1.12) in MM.
PV/PA and Class of Heart Failure
The PV/PA ratio increased with class of heart failure
(Fig 4). The PV/PA ratio was signiﬁcantly lower in con-
trol dogs compared to dogs with DMVD in ISACHC
class IB (2D, 1.63; range, 1.42–1.76; MM, 1.60; range,
1.34–1.82), II (2D, 2.36; range, 1.89–2.53; MM, 2.02;
range, 1.96–2.35) and III (2D, 2.55; range, 2.24–2.83;
MM, 3.07; range, 1.78–3.43; P < .001). The PV/PA also
was lower in DMVD dogs in class IA (2D, 1.23; range,
1.14- 1.40; MM, 1.15; range, 1.01–1.35) compared to
dogs in class II (P < .001) and III (P = .001). Doppler-
echocardiographic variables according to ISACHC class
are summarized in Table 2. Regardless of the mode,
PV/PA was correlated with other echocardiographic
indices of left ventricular ﬁlling pressures such as the
indexed left atrial and left ventricular sizes and the E/A
ratio (Table 3).
PV/PA and Radiographic Score
Thoracic radiographs were available for 13 controls
and 43 (70%) dogs with DMVD. A radiographic
diagnosis of CHF was made in 39% of dogs with
DMVD. The 13 control dogs had no evidence of CHF
and had a total radiographic score of 0, 1, or 2. Dogs
with a radiographic diagnosis of CHF had higher PV/
PA ratios (2D, 2.39; range, 1.89–2.56; MM, 2.16; range,
1.86–2.63) than dogs without CHF on thoracic radio-
graphs (2D, 1.19; range, 1.02–1.41; MM, 1.09; range,
0.96–1.35; P < .001; Fig 5). The PV/PA was signiﬁ-
cantly correlated with radiographic composite score
(2D, r = 0.66; P < .001; MM, r = 0.65; P < .001).
The receiver operating characteristic (ROC) curve
analysis indicated that the PV/PA ratio measured in 2D
and MM was useful to distinguish dogs with CHF (di-
agnosed by radiography) from dogs without CHF
A B
C D
Fig 2. Scatter plots of BW to PV diameter measured in 2D (A) and MM (C) and BW to PA diameter measured in 2D (B) and MM (D)
in 37 healthy dogs. 2D, bidimensional; BW, Body weight; MM, M-mode; PA, Pulmonary artery; PV, Pulmonary vein.
Fig 3. Scatter plots of PV/PA ratio obtained in 2D and MM
illustrating high correlation between both methods. r = 0.90;
P < .001. 2D, bidimensional; MM, M-mode; PV/PA, pulmonary
vein diameter to pulmonary artery diameter.
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(Fig 6). Area-under-the receiver-operating characteristic
curves (AUC) was 0.98 (CI, 0.97–0.98) for both 2D and
MM. A cut-oﬀ value of 1.7 in 2D and 1.6 in MM pre-
dicted CHF in DMVD dogs with sensitivity of 96%
(CI, 77–100) and 87% (CI, 67–96) and speciﬁcity of
91% (CI, 75–97) and 94% (CI, 79–99), respectively.
Discussion
The diagnosis of CHF in dogs with DMVD relies on
a combined interpretation of clinical signs and results
of ≥1 diagnostic tools including thoracic radiography,
NT-proBNP or Doppler echocardiography. Pulmonary
venous congestion suggests increased pulmonary venous
pressure, the trigger factor for development of pul-
monary edema. The principal ﬁnding of our study is
that, PV/PA, a new echocardiographic index of pul-
monary venous congestion, increases with heart failure
severity in dogs with DMVD. Using a cut-oﬀ value of
1.7 in 2D, PV/PA diﬀerentiates dogs with CHF from
dogs without CHF with high accuracy using thoracic
radiographs as the gold standard.
Interobserver Variability and Normal Values of PV/
PA
Assessment of observer variability is an essential step
in the evaluation of the diagnostic value of a measure-
ment. The interobserver CV for image acquisition and
measurements ranged from 4 to 8% which indicated
good to excellent reproducibility. We also found that
both measurement methods were highly correlated. In
A B
Fig 4. Box plot illustrating PV/PA ratio in bi-dimensional mode (A) and M-mode (B) according to heart failure classes. The whiskers
indicate the range of values. The box contains the 25th–75th centiles. The line within the box indicates the median and the cross indicates
the mean. 2D, bi-dimensional; MM, M-mode; PV/PA, pulmonary vein diameter to pulmonary artery diameter. *Signiﬁcantly diﬀerent from
control group (P < .001). °Signiﬁcantly diﬀerent from ISACHC IA group (P = .001).
Table 2. Echocardiographic variables for 61 dogs and radiographic scores for 43 dogs with diﬀerent classes of heart
failure.
ISACHC IA ISACHC IB ISACHC II ISACHC III
LA/Ao 1.39 (1.33–1.46) 1.61 (1.54–1.73) 2.28 (1.94–2.61) 2.48 (2.11–2.82)
LAmin/Ao 1.78 (1.67–1.81) 2.09 (1.99–2.26) 2.89 (2.50–3.22) 2.93 (2.69–3.5)
nLVIDd (cm/kg) 1.52 (1.40–1.60) 1.72 (1.60–1.84) 2.11 (2.01–2.27) 2.27 (2.04–2.31)
EDVI (mL/m2) 45.8 (38.1–53.3) 53.9 (46.0–62.0) 86.4 (75.0–90.8) 94 (89–105.4)
E/A 1.05 (0.78–1.29) 1.31 (1.01–1.38) 1.90 (1.56–2.41) 1.90 (1.7–2.26)
TR (mmHg) 23 (10.2–34) {6/16} 22.8 (17.3–33.0) {5/16} 36.9 (29.5–44.3) {13/20} 37.3 (27.0–49.7) {8/9}
Radiographic composite score 1 (0–3) 2 (0–4) 4 (1–7) 5 (4–7)
Median (IQR) for continuous data and median (range) for categorical data; {} = number of dogs with TR. Ao, Aorta; EDVI, Indexed
end-diastolic volume; IQR, interquartile range; LA, Left atrium; nLVIDd, Normalized left ventricular internal diameter in diastole; TR,
Tricuspid regurgitation.
Table 3. Correlation between PV/PA and other echocardiographic parameters.
LA/Ao LAmin/Ao nLVIDd EDVI E/A
PV/PA 2D 0.77 (<0.001) 0.74 (<0.001) 0.76 (<0.001) 0.72 (<0.001) 0.62 (<0.001)
PV/PA MM 0.74 (<0.001) 0.75 (<0.001) 0.70 (<0.001) 0.62 (<0.001) 0.58 (<0.001)
Coeﬃcient of correlation (P value).
2D, bidimensional; MM, M-mode; Ao, Aorta; EDVI, Indexed end-diastolic volume; LA, Left atrium; nLVIDd, Normalized left ventricu-
lar internal diameter in diastole.
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our study, suggested reference values for the PV/PA
ratio in healthy dogs were approximately 1 in 2D and
MM, based on data from 37 dogs. These reference
ranges are in accordance with a previous report describ-
ing a mean PV/PA ratio of 1 in MM with SD of 0.11.17
A PV/PA value of 1 might therefore be used in future
studies as a reference value for healthy dogs.
Diagnosis of CHF by PV/PA
Increased left ventricular ﬁlling pressure is a key fea-
ture of left-sided CHF, with therapeutic and prognostic
signiﬁcance, in dogs with DMVD. However, this hemo-
dynamic variable cannot be directly measured in a non-
invasive manner prompting a search for accurate
surrogate markers. As DMVD progresses, the left
atrium and ventricle gradually enlarge. Subsequently,
left atrial pressure, which is dependent on the regurgi-
tant volume, chamber compliance and pulmonary
venous pressure, increases. This increase can lead, in a
subset of dogs with DMVD, to left-sided CHF. In dogs
with DMVD, left atrial size, as assessed by the ratio of
LA/Ao, has been shown to increase with increasing
class of heart failure,23 to be associated with decreased
survival time2,7,24 and to predict CHF.16,24 A similar
scenario might be expected for pulmonary vein size, but
this has not been studied in dogs. We anticipate that in
the absence of congenital heart disease (left-to-right
shunt or pulmonic stenosis) and in the absence of pul-
monary hypertension, the right pulmonary artery diam-
eter should be relatively stable. Therefore, in
uncomplicated DMVD, an increase of PV diameter
(and PV/PA) is expected. In this study, PV/PA
increased with increasing class of heart failure. Further-
more, dogs identiﬁed to be in CHF by thoracic radiog-
raphy had higher PV/PA values than did asymptomatic
dogs. The increase of PV/PA is likely related to pul-
monary vein enlargement. This variable had an AUC
>0.9 indicating excellent diagnostic performance for
CHF detection. A PV/PA value >1.7 in 2D predicted
CHF with an accuracy >90%, a sensitivity of 96%, and
a speciﬁcity of 91%. This variable had an AUC > 0.9,
indicating excellent diagnostic performance for CHF
detection. Theoretically, the presence of concurrent pul-
monary hypertension could contribute to false negative
results by decreasing the PV/PA ratio. In our study, the
presence of pulmonary hypertension did not interfere
with CHF diagnosis performed by echocardiographic
BA
Fig 5. Median and scatter plots of PV/PA measured in 2D (A) or in MM (B) in 19 dogs with compensated DMVD and in 23 dogs with
DMVD and radiographic evidence of CHF. White dots correspond to dogs with evidence of mild to moderate pulmonary hypertension
(pressure gradient > 36 mmHg). 2D, bidimensional; CHF; Congestive heart failure; DMVD, degenerative mitral valve disease; MM,
M-mode; PV/PA, pulmonary vein diameter to pulmonary artery diameter. *Signiﬁcantly diﬀerent from groups without CHF (P < .001).
A B
Fig 6. Receiver-operating characteristic (ROC) curve illustrating PV/PA ratio measured in 2D (A) and M-Mode (B) that distinguishes
asymptomatic from decompensated dogs with degenerative mitral valve disease. 2D, bidimensional; AUC, Area under the curve; PV/PA,
pulmonary vein diameter to pulmonary artery diameter.
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assessment of PV/PA. Other factors that might inﬂu-
ence PV/PA values include an absence of venous con-
gestion as sometimes is observed in acute CHF caused
by chordae tendinae rupture, diﬀerences in pulmonary
venous tone or compliance, and the presence of an
abnormally small or large PA.
Comparison with Other Doppler-echocardiographic
Indices of CHF
Each Doppler-echocardiographic-derived surrogate
measure for left ventricular ﬁlling pressure has its own
limitations. Evaluation of ﬁlling pressures depends on
an integrated interpretation of volume overload remod-
eling indices as well as indices of left ventricular ﬁlling.
In our study, PV/PA correlated with left atrial and ven-
tricular size, echocardiographic parameters of volume
overload already known to identify CHF.24 We also
showed that in dogs with DMVD, PV/PA was corre-
lated with mitral E/A ratio. Transmitral ﬂow patterns
may identify diastolic dysfunction and increased left
ventricular ﬁlling pressures, but these variables are
interrelated.25 The diagnostic accuracy of E/A for CHF
detection may be limited in dogs with DMVD because
of the large inﬂuence of volume overload on left ven-
tricular ﬁlling. Furthermore, the inﬂuence of preload on
early diastolic tissue velocity (E0) in mitral regurgitation
explains why identiﬁcation of CHF using the E/E0 ratio
is less accurate in DMVD than in dilated cardiomyopa-
thy.16 The ratio between E and the isovolumetric relax-
ation time has been shown to be the optimal Doppler
index for identifying CHF in dogs with DMVD.16 How-
ever, these measurements require Doppler mode and a
high level of expertise, and can prolong the duration of
echocardiographic examination. On the contrary, the
PV/PA ratio is relatively simple to obtain by conven-
tional 2D or MM echocardiography.
Limitations
This study has several limitations. Left ventricular ﬁll-
ing pressures were not directly measured and thoracic
radiography was used as the gold standard to assess the
presence or absence of CHF. The sensitivity and speci-
ﬁcity of thoracic radiography are unknown and are
observer dependent.5,6 Second, a majority of dogs in
CHF were on treatment to decrease venous pressure
before their examination, and this could have con-
founded interpretation of both Doppler-echocardio-
graphic variables and thoracic radiographs. Third, the
relatively small population studied rendered the study
underpowered especially for comparison of PV/PA
among classes of heart failure. Additional studies evalu-
ating the accuracy of PV/PA to predict CHF in DMVD
dogs using the pre-established cut-oﬀ value are indicated.
Conclusion
Despite these limitations, our study has demonstrated
that PV/PA is a simple and reproducible echocardio-
graphic variable that can be obtained by 2D or MM
echocardiography. In DMVD dogs, PV/PA increases
with increasing stage of heart failure. Using a cut-oﬀ
value of 1.7 in 2D, PV/PA permitted accurate discrimi-
nation of dogs in CHF from asymptomatic dogs. Addi-
tional studies are required to determine if PV/PA might
provide additional information in the integrated inter-
pretation of Doppler-echocardiographic indices of left
ventricular ﬁlling pressure. This measure also could
have potential value in the rapid assessment of CHF in
dogs in a critical care setting.
Footnotes
a Vivid I, General Electric Medical System, Waukesha, WI
b Xlstat 2014.6.01, Addinsoft, Paris, France
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